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Background: Alpha-1 antitrypsin (AAT) is one of the primary circulating 
serum antiproteases in humans.  It inhibits a variety of serine proteinases, 
with neutrophil elastase being one of the most physiologically important, 
as well as inhibiting a number of metallo-proteinases and other pro-
inflammatory and pro-apoptotic molecules.  AAT is normally produced 
within hepatocytes and macrophages, where hepatocyte-derived AAT 
forms the bulk of the physiologic reserve of AAT.  AAT deficiency is a 
genetic disorder caused by defective production of this protein and 
deposition of increased abnormal AAT protein in liver cells.  Gene therapy 
is an experimental technique that uses genes to treat or prevent disease. 
Gene therapy approaches have been conducted in patients with AAT 
deficiency with successful AAT expression, but not to the therapeutic 
levels required to reduce the risk of emphysema.  Codon optimization, a 
somewhat new and evolving technique in the world of gene therapy, is 
used by many scientists to maximize protein expression in living 
organisms by altering translational and transcriptional efficiency as well as 
protein refolding.  With this technique, it is thought higher AAT levels can 
be achieved.  
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Figure 1. Protease-induced lung damage.  With abnormally functioning 
alpha-1 antitrypsin (AAT), neutrophil elastase is constitutively expressed. 
The results obtained are quite perplexing.  It is under general knowledge 
that genetic cloning is a delicate and somewhat repetitious technique.  
That being said, it still does not explain why the single stranded AAT 
construct containing the long intron expressed more AAT than the double 
stranded, self-complementary optimized construct.  One reason could be 
that the single stranded AAT was prepared and isolated from a larger 
plasmid preparation, which can account for a higher concentration of DNA.  
What is so striking is that the concentration for the cell lysis sample is 
almost 5 fold that of the optimized AAT.  In order to fully elucidate the 
advantage of codon optimization, the 2 remaining constructs need to be 
cloned and all of the isolated plasmid DNA should be prepared on the 
same scale to minimize any other confounding variables.  
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Alpha 1-antitrypsin deficiency is a genetic disorder caused by defective 
production of alpha 1-antitrypsin (AAT).  Gene therapy approaches have 
been conducted in patients with AAT deficiency with successful AAT 
expression, but not to the therapeutic levels required to reduce the risk of 
emphysema.  Codon optimization, a somewhat new and evolving 
technique, is used by many scientists to maximize protein expression in 
living organisms by altering translational and transcriptional efficiency as 
well as protein refolding.  The purpose of this study was to develop 
single stranded and double stranded AAT gene constructs, test their 
protein expression in vitro, and compare with those levels expressed by 
the AAT construct that is currently in clinical trials.  Three constructs were 
to be developed, yet only one construct was successfully cloned.  This 
clone, optimized ds-CB-AAT, illustrated increased AAT protein expression 
as the transfection time increased.  However, protein levels were 
appreciably lower in the optimized construct compared to the single 
stranded (long intron) AAT construct that is currently being administered 
in clinical trials. The data did not suggest that the optimized AAT 
construct does in fact express more AAT protein in vitro as expected.  In 
order to achieve data that can be reproduced, the 2 remaining constructs 
need to be cloned and all of the isolated plasmid DNA should be 
prepared on the same scale to minimize any additional confounding 
variables.  
 
Figure 2. Factors influencing protein expression. Several factors that act 
along the path of expression from DNA to mRNA to protein are shown, 
any of which could be altered by or could affect the impact of gene 
design. RBS, ribosome-binding site.  
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Figure 5.  AAT protein expression in vitro.  Supernatant from HEK 293 
cells that were transfected with CB-AAT and optimized ds-CB-AAT 
constructs were collected and AAT levels were measured through ELISA. 
 The gene construct that is currently being used in clinical trials is single 
stranded containing a long intron.  The following constructs were to be 
cloned for comparing protein levels in vitro: 
 
• Double stranded, self-complementary AAT (short intron) 
• Double stranded, self-complementary, optimized AAT 
• Single stranded optimized AAT 
  
 Each clone started with a DNA enzyme digestion of each insert and 
vector that then underwent ligation.  Regular efficiency transformation 
was then carried out for bacterial replication.  The plasmid DNA was 
then collected and isolated from each colony that formed on the agar 
plate.  After enzymatically digesting the isolated DNA to test if the 
correct construct was obtained, the DNA was then transfected into HEK 
293 cells using Lipofectamine.  Serum was then collected after 24 and 
48 hours as well as after cell lysis to test for AAT protein expression 
with human AAT ELISA, per protocol. 
 
Figure 3.  GFP transfection control.  HEK 293 cells expressing green 
fluorescent protein (GFP) indicating successful transfection. 
 
Figure 4. Histology and immunochemical study of skeletal muscle. (A) H&E-
stained section showing moderate endomysial inflammatory reaction 
composed primarily of mononuclear cells. (B) H&E-stained section showing a 
marked endomysial inflammatory reaction. (C) Immunohistochemistry for AAT, 
showing granular reactivity in myofibers on cross-section. (D) 
Immunohistochemistry for AAT, showing granular activity in myofibers cut 
longitudinally. (E) Immunohistochemistry for CD3, showing a high proportion of 
T lymphocytes comprising the inflammatory infiltrate. (F) CD8-immunoreactive 
T cells comprise a significant subset of total lymphocytic infiltrate. 
Figure 6.  Gel electrophoresis of successful clone of optimized ds-CB-
AAT.  Optimized ds-CB-AAT was cut with XmnI enzyme that yielded the 
two desired bands of 4084bp and 1591bp with a 1Kb ladder for 
comparison. 
